1-3 of 3
Lionel D. Lewis
Close
Sort by
Journal Articles

Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103

Clinical Trials & Observations
Chaitra S. Ujjani, Sin-Ho Jung, Brandelyn Pitcher, Peter Martin, Steven I. Park, Kristie A. Blum, Sonali M. Smith, Myron Czuczman, Matthew S. Davids, Ellis Levine, Lionel D. Lewis, Scott E. Smith, Nancy L. Bartlett, John P. Leonard, Bruce D. Cheson
Journal: Blood
Blood (2016) 128 (21): 2510–2516.
https://doi.org/10.1182/blood-2016-06-718106
Published: 2016
Journal Articles

Efficacy and Safety of YM155 in Relapsed/Refractory Non-Hodgkin’s Lymphoma Patients Enrolled in a Phase I Study.

Kyriakos Papadopoulos, MD, Alain Mita, MD, Scott Antonio, MD, Lionel D. Lewis, MD, N.J. Reddy, Elizabeth Till, J.J. Mahany, Anne Keating, DPharm, Amanda Seiz, Pamela Bartels, Anthony Tolcher, MD
Journal: Blood
Blood (2007) 110 (11): 3422.
https://doi.org/10.1182/blood.V110.11.3422.3422
Published: 2007
Journal Articles

Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma

Clinical Trials & Observations
Peter Borchmann, Roland Schnell, Irene Fuss, Oliver Manzke, Thomas Davis, Lionel D. Lewis, Detlev Behnke, Claudia Wickenhauser, Petra Schiller, Volker Diehl, Andreas Engert
Journal: Blood
Blood (2002) 100 (9): 3101–3107.
https://doi.org/10.1182/blood-2001-12-0295
Published: 2002